Login to Your Account



Anti-CD38 Darzalex combo reduces MM progression by 61%

By Karen Pihl-Carey
Staff Writer

Monday, June 6, 2016

CHICAGO – In what could change the standard of care for advanced MM patients, daratumumab reduced the risk of cancer progression by 61 percent and doubled partial and complete response rates by being added to Velcade and dexamethasone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription